Arena virus monoclonal antibodies and uses

Inventors

Branco, Luis M. • Garry, Robert F. • Robinson, James E. • SAPHIRE, Erica O. • HASTIE, Kathryn M. • Geisbert, Thomas W.

Assignees

Boad Of Regents Of University Of Texas System • Scripps Resesrch Institute • Zalgen Labs LLC • Scripps Research Institute • Tulane University • The University of Texas System

Abstract

Disclosed herein are compositions comprising recombinant arenavirus monoclonal antibodies and antigen-binding fragments thereof, as well as therapeutic methods using the antibodies. In some embodiments, the antibodies provide pan-arenavirus protection against a number of arenavirus types and strains.

Core Innovation

The invention relates to recombinant human monoclonal neutralizing antibodies and neutralizing antigen-binding antibody fragments specific for Lassa virus glycoprotein. The antigen-binding compositions are defined by specified V_H CDR1, V_H CDR2, V_H CDR3, V_L CDR1, V_L CDR2, and V_L CDR3 sequence identities.

In one embodiment, the antigen-binding composition comprises a combination of three recombinant human monoclonal neutralizing antibodies or neutralizing antigen-binding antibody fragments thereof having defined CDR sequence identities. The disclosure is framed around antigen-binding compositions for Lassa virus and lymphocytic choriomeningitis virus infections and broader arenavirus neutralizing antibody embodiments.

The invention further includes pharmaceutical compositions with pharmaceutically acceptable carriers and administering the claimed antigen-binding compositions to treat or prevent Lassa virus and lymphocytic choriomeningitis virus infections in a subject. The document also discloses diagnostic kits with labeled antibodies and therapeutic administration.

Claims Coverage

The partial claim set includes three independent claims. The coverage centers on antigen-binding compositions based on recombinant human monoclonal neutralizing antibodies or neutralizing antigen-binding antibody fragments specific for Lassa virus glycoprotein, defined by specific V_H and V_L CDR sequence identities, with dependent claims addressing fragment formats, pharmaceutical compositions with pharmaceutically acceptable carriers, and treatment or prevention by administration.

Overall, the independent claim coverage is directed to antigen-binding compositions based on recombinant human monoclonal neutralizing antibodies or neutralizing antigen-binding antibody fragments specific to Lassa virus glycoprotein and defined by particular V_H and V_L CDR sequence identities. The provided claim summaries further indicate dependent coverage for pharmaceutical compositions, fragment selection, and treating or preventing Lassa virus and lymphocytic choriomeningitis virus infection by administering the claimed compositions.

Stated Advantages

Documented Applications